These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37318805)

  • 1. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
    Nguemeni Tiako MJ; Dolan A; Abrams M; Oyekanmi K; Meisel Z; Aronowitz SV
    JAMA Netw Open; 2023 Jun; 6(6):e2318487. PubMed ID: 37318805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.
    Keshwani S; Maguire M; Goodin A; Lo-Ciganic WH; Wilson DL; Hincapie-Castillo JM
    JAMA Health Forum; 2022 Jun; 3(6):e221757. PubMed ID: 35977240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
    Bachhuber MA
    Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.
    Andrews CM; Westlake MA; Abraham AJ; Grogan CM; Harris SJ; Jehan S
    Health Aff (Millwood); 2024 Jan; 43(1):55-63. PubMed ID: 38190595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
    Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
    Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.
    Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM
    JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017.
    Huskamp HA; Riedel LE; Barry CL; Busch AB
    Med Care; 2018 Jun; 56(6):505-509. PubMed ID: 29668645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
    Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
    Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
    Doshi JA; Puckett JT; Parmacek MS; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003939. PubMed ID: 29326146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
    Barenie RE; Sinha MS; Kesselheim AS
    Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
    Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
    Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B; Levin J; Chang HY; Jones C; Alexander GC
    JAMA Netw Open; 2018 Aug; 1(4):e181588. PubMed ID: 30646116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid coverage of medications to treat alcohol and opioid dependence.
    Mark TL; Lubran R; McCance-Katz EF; Chalk M; Richardson J
    J Subst Abuse Treat; 2015 Aug; 55():1-5. PubMed ID: 25921475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.